These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 37960733

  • 1. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review.
    Huang W, Liu Y, Li M, Xue Y, Bao W, Guo Y.
    Medicine (Baltimore); 2023 Nov 10; 102(45):e35946. PubMed ID: 37960733
    [Abstract] [Full Text] [Related]

  • 2. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P, Liu S, Cao H.
    J Med Case Rep; 2024 Jan 22; 18(1):51. PubMed ID: 38247005
    [Abstract] [Full Text] [Related]

  • 3. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Jan 22; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 4. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
    Lin SH, Zhang A, Li LZ, Zhao LC, Wu LX, Fang CT.
    BMC Endocr Disord; 2022 Sep 24; 22(1):239. PubMed ID: 36153581
    [Abstract] [Full Text] [Related]

  • 5. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X, Yang M, Wang L, Li L, Zhong X.
    Medicine (Baltimore); 2021 May 14; 100(19):e25795. PubMed ID: 34106616
    [Abstract] [Full Text] [Related]

  • 6. Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab.
    Jouneghani NS, Phillip J, Dasanu CA.
    J Oncol Pharm Pract; 2022 Apr 14; 28(3):722-724. PubMed ID: 34791931
    [Abstract] [Full Text] [Related]

  • 7. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Apr 14; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 8. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
    Popa LG, Giurcaneanu C, Portelli MG, Mihai MM, Beiu C, Orzan OA, Ion A, Anghel TH.
    Medicina (Kaunas); 2024 Feb 22; 60(3):. PubMed ID: 38541099
    [Abstract] [Full Text] [Related]

  • 9. [Immune Checkpoint Inhibitors Related Diabetes Mellitus: 
A Report of 2 Cases and Literature Review].
    Ren Y, Zhang L, Wang Y, Zhong D.
    Zhongguo Fei Ai Za Zhi; 2022 Jan 20; 25(1):61-65. PubMed ID: 35078286
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immune checkpoint inhibitors-induced diabetes mellitus (review).
    Chen J, Hou X, Yang Y, Wang C, Zhou J, Miao J, Gong F, Ge F, Chen W.
    Endocrine; 2024 Nov 20; 86(2):451-458. PubMed ID: 38955861
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
    Goff CB, Plaxe SC, White W, Dasanu CA.
    J Oncol Pharm Pract; 2023 Jul 20; 29(5):1259-1263. PubMed ID: 36734125
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.
    Luo J, Feng J, Liu C, Yang Z, Zhan D, Wu Y, Pan L, Zhang L.
    J Int Med Res; 2022 Sep 20; 50(9):3000605221121940. PubMed ID: 36171723
    [Abstract] [Full Text] [Related]

  • 19. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J.
    J Diabetes; 2017 Oct 20; 9(10):890-893. PubMed ID: 28661564
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.